NEW
YORK, June 9, 2023 /PRNewswire/ -- Jakubowitz
Law announces that an investigation into potential securities
fraud allegations has commenced on behalf of
shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
To be contacted by a member of our team, fill out the
form:
https://claimyourloss.com/securities/phathom-class-action-loss-submission-form/?id=40552&from=4
Further details on the investigation: On August 2, 2022, before market hours, Phathom
issued a press release entitled "Phathom Pharmaceuticals Reports
Second Quarter 2022 Financial Results and Provides Business
Updates" which announced that "we detected trace levels of a
nitrosamine in vonoprazan drug product in our post-approval testing
as we prepared for commercial launch." Further, the press release
announced that "[t]he Company is working with the FDA and plans to
obtain approval of and implement an additional test method,
specification, including a proposed acceptable intake limit, and
additional controls to address this impurity prior to releasing our
first vonoprazan-based products to the market." Finally, Phathom
announced that "[t]hese additional activities will result in a
delay of the planned VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK
product launches." On this news, Phathom's stock price
fell $2.61 per share, or 28%, to
close at $6.46 per share on
August 2, 2022.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/phat-fraud-alert-jakubowitz-law-is-investigating-phathom-pharmaceuticals-inc-in-connection-with-potential-violations-of-federal-securities-laws-301846746.html
SOURCE Jakubowitz Law